How Has the Atrial Septal Defect Market Size Evolved in Recent Years?
The atrial septal defect market has seen considerable growth due to a variety of factors.
• The atrial septal defect market has seen steady growth in recent years. It is expected to grow from $4.14 billion in 2024 to $4.47 billion in 2025, at a compound annual growth rate (CAGR) of 8.0%.
This growth is driven by a rise in congenital heart disease cases, increased research and development funding, heightened awareness of heart defects, higher pediatric surgery rates, new ASD closure device approvals, and expanding healthcare facilities.
What Are The Predictions for The Atrial Septal Defect Market in the Coming Years?
The atrial septal defect market is expected to maintain its strong growth trajectory in upcoming years.
• The atrial septal defect market is projected to grow significantly, reaching $6.03 billion by 2029, with a CAGR of 7.7%.
This is driven by the increased use of telemedicine for care, personalized treatment plans, increased healthcare spending, the aging population, and better device regulation. Trends include the development of minimally invasive ASD closure devices, AI-driven diagnostics, biodegradable materials for device manufacturing, and remote monitoring technologies for patient recovery.
Which Drivers Are Accelerating Growth In The Atrial Septal Defect Market?
The rising occurrence of congenital heart defects (CHD) is expected to drive the atrial septal defect market. CHD refers to heart abnormalities present from birth, and the growing number of diagnoses is increasing the need for treatments like atrial septal defect management, which addresses abnormal blood flow between the heart's chambers. For example, a June 2024 report by the Australian Institute of Health and Welfare noted that about 65,000 Australians live with congenital heart disease, with 79 infant deaths attributed to it. Hence, the prevalence of congenital heart defects is fueling the growth of the atrial septal defect market.
What Are The Core Segments Of The Global Atrial Septal Defect Market?
The atrial septal defect market covered in this report is segmented –
1) By Treatment Procedure: Surgical Closure, Transcatheter Closure, Hybrid Procedures, Medication Therapy
2) By Diagnosis: Chest X-Ray, Electrocardiogram, Cardiac Catheterization, Transesophageal Echocardiography, Pulse Oximetry
3) By Product Type: Medical Devices, Pharmaceutical Products
4) By Age Group: Pediatric, Adult
5) By End-User: Hospitals, Ambulatory Surgical Centers, Cardiac Clinics, Other End-Users
Subsegments:
1) By Surgical Closure: Open Heart Surgery (Traditional Surgical Closure), Minimally Invasive Surgical Closure, Patches (Pericardial, Synthetic) For Asd Closure
2) By Transcatheter Closure: Device-Based Closure (Amplatzer Septal Occluder), Transcatheter Plug Closure Techniques, Catheter-Based Asd Repair For Adult And Pediatric Patients
3) By Hybrid Procedures: Combination Of Surgical And Transcatheter Techniques, Minimally Invasive Hybrid Procedures, Hybrid Closure For Complex Or Large Asds
4) By Medication Therapy: Anticoagulant Therapy (To Prevent Stroke), Diuretics (For Managing Symptoms), Antihypertensive Drugs (For Managing Associated Conditions), Off-Label Use Of Other Medications
Pre-Book The Atrial Septal Defect Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Trends Are Shaping The Atrial Septal Defect Market?
Companies in the arterial septal defect market are focusing on advancing devices and seeking approvals to expand their use. Device approval is necessary for obtaining regulatory certification before devices can be marketed and used. For example, in March 2024, Occlutech GmbH, a Sweden-based company specializing in minimally invasive cardiac devices, announced FDA approval for the Occlutech ASD Occluder and Occlutech Pistol Pusher for treating atrial septal defects. This approval marks a key step in Occlutech's global healthcare advancement. The Occluder is a self-expanding nitinol device with flexible discs, designed for long-term use in patients with confirmed ASD defects.
Who Are the Key Players In The Atrial Septal Defect Market?
Major companies operating in the atrial septal defect market are:
• Abbott Laboratories
• Medtronic plc
• Siemens Healthineers
• Boston Scientific Corporation
• Philips Healthcare
• Edwards Lifesciences Corporation
• W. L. Gore & Associates Inc.
• St. Jude Medical LLC
• Cook Medical
• Lepu Medical Technology Co. Ltd.
• MicroPort Scientific Corporation
• Lifetech Scientific Corporation
• Venus Medtech Hangzhou Inc
• Occlutech Holding AG
• Coherex Medical
• Osypka AG
• Arjo AB
• Heart Medical Europe BV
• AtriCure Inc.
• Asklepion Pharmaceuticals LLC
What Are The Regional Insights Into The Atrial Septal Defect Market?
North America was the largest region in the atrial septal defect market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the atrial septal defect market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
